NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study)

/PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd., announced today that it has received preliminary analysis results from...

Related Keywords

United States ,Japan ,Tsugio Tanaka ,Drug Administration ,Nippon Shinyaku Co Ltd ,Prnewswire Ns Pharma Inc ,Source Ns Pharma Inc ,Ns Pharma Inc ,President Tsugio Tanaka ,Priority Review ,Rare Pediatric Disease ,Orphan Drug ,Fast Track ,Conditional Early Approval ,Safety Information ,Medical Information ,Duchenne Muscular Dystrophy ,